Multiple sclerosis (MS) is a complex disorder of the central nervous system, causing inflammation, demyelination and axonal damage. A limited number of genetic risk factors for MS have been identified, but the etiology of the disease remains largely unknown. For the identification of genes regulating neuroinflammation we used a rat model of MS, myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE), and carried out a linkage analysis in an advanced intercross line (AIL). We thereby redefine the Eae18b locus to a 0.88 Mb region, including a cluster of chemokine genes. Further, we show differential expression of Ccl2, Ccl11 and Ccl11 during EAE in rat strains with opposite susceptibility to EAE, regulated by genotype in Eae18b. The human homologous genes were tested for association to MS in 3841 cases and 4046 controls from four Nordic countries. A haplotype in CCL2 and rs3136682 in CCL1 show a protective association to MS, whereas a haplotype in CCL13 is disease predisposing. In the HLA-DRB1*15 positive subgroup, we also identified an association to a risk haplotype in CCL2, suggesting an influence from the human leukocyte antigen (HLA) locus. We further identified association to rheumatoid arthritis in CCL2, CCL8 and CCL13, indicating common regulatory mechanisms for complex diseases.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, causing demyelination and axonal damage. The etiology is largely unknown, but a number of genetic variants contributing to susceptibility are identified, including HLA-DRB1,
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4,5 and IL2RA. 5 Complex disorders involving chronic inflammation and dysregulation of the immune system may share common genetic risk factors. 6 Examples of genes associated to several inflammatory diseases include IRF5, which is associated to systemic lupus erythematosus, 7 rheumatoid arthritis (RA), 8 inflammatory bowel disease 9 and MS 10 , and CLEC16A, associated to MS 11 and type I diabetes. [12] [13] [14] Identification of mediators of inflammation and other pathogenic mechanisms is crucial for the understanding of the disease, and experimental models have successfully been applied in positional cloning and functional studies of genes that regulate complex human diseases, including CTLA-4 15 and CBLB. 16 To identify genetic regions that influence severity and susceptibility to neuroinflammation, we have used a rat model of MS, myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE), and carried out a linkage analysis in an advanced intercross line (AIL). The aim was to identify candidate genes in a previously identified locus, Eae18b, on rat chromosome 10. 17-19 This genetic region is also a candidate region for different rat models of arthritis [20] [21] [22] and the homologous region on human chromosome 17 showed suggestive linkage in a meta analysis of linkage studies in MS. 23 Eae18b contains a number of interesting candidate genes for MS and other inflammatory disorders, including a cluster of chemokine genes. Chemokines are small proteins with chemotactic and immunoregulatory properties, which are important for guiding leukocyte trafficking, in health and during inflammation. 24, 25 There is evidence for a role of specific chemokines in regulation of disease and cell migration in both MS 26 and EAE. 27 The chemokine genes have also been included in linkage and association studies, [28] [29] [30] [31] but despite substantial evidence for linkage and association to this chemokine cluster, data lack conclusive replication. 32 In this study, we refine the Eae18b locus to a 0.88 Mb region containing the chemokine gene cluster and show that the expression of chemokines Ccl2, Ccl11 and Ccl1 is regulated by the locus. We further present evidence for association of CCL2, CCL1 and CCL13 in a large Nordic MS material, including a possible modulatory effect from the human leukocyte antigen (HLA)-DR1*15 locus.
Materials and methods
Advanced intercross line
The AIL 33 used in this study originated from the EAEsusceptible DA and EAE-resistant PVG.av1 rat strains that share the RT1.AV1 MHC-haplotype, thus allowing the identification of non-MHC genes regulating disease. The AIL was produced as previously described. 34 Inbred DA rats were originally obtained from the Zentralinstitut fü r Versuchstierzucht (Hannover, Germany) and PVG.av1 rats from Harlan UK (Blackthorn, UK). Animals were bred and housed at the Karolinska University Hospital (Stockholm, Sweden), in polystyrene cages containing aspen wood shavings with free access to water and standard rodent chow and a 12 h light-dark cycle. The animals were routinely monitored for pathogens according to a health-monitoring program for rats at the National Veterinary Institute, in Uppsala, Sweden. The local ethical committee in northern Stockholm approved the experiments.
EAE induction and phenotypic evaluation
Recombinant MOG (amino acids 1-125 from the N-terminus) was expressed in Escherichia coli and purified to homogeneity by chelate chromatography as previously described. 35 The purified protein, dissolved in 6 M urea, was dialyzed against PBS to obtain a semiprecipitated preparation that was stored at À20 1C. Rats between 8 and 16 weeks of age were anesthetized with isofluorane (Forene, Abbott Laboratories, Abbot Park, IL, USA) and immunized with a single subcutaneous injection in the dorsal base of the of the tail with 200 ml of inoculum containing rMOG (amino acids 1-125) (20 mg per rat) in saline emulsified with IFA (Sigma Aldrich, St Louis, MO, USA), ratio 1:1. The rats were weighed and monitored daily for clinical signs of EAE from days 7 to 10 until the end of the experiment, that is 31-38 days post immunization. The clinical score was graded as follows: (0) no clinical signs of EAE; (1) tail weakness or tail paralysis; (2) hind leg paraparesis or hemiparesis; (3) hind leg paralysis or hemiparalysis; (4) tetraplegia or moribund; and (5) death. The following clinical parameters were assessed for each animal: EAE incidence (clinical signs for 41 day), onset of EAE (the first day that clinical signs were observed), maximum EAE score (the highest clinical score observed during EAE), cumulative EAE score (the sum of daily clinical scores), duration of EAE (the number of days with EAE) and weight loss ([weight at day 8 p.i.Àminimum weight during the experiment]/weight at day 8 p.i.).
Genotyping in rats
Genotyping of animals was carried out on DNA extracted from ear or tail tip tissues according to a standard protocol. 36 In total, 794 rats were genotyped (428 females and 366 males) corresponding to 772 clinically monitored rats and 22 additional rats, for which phenotypic data could not be obtained because of death after anesthesia. The incidence of EAE was 29%, affecting 152 females and 72 males, as previously described. 34 The region analyzed in the G10 AIL includes the Eae18b region previously linked to MOG-EAE. 19 The 7.93 Mb region delimited by markers D10Arb27 and D10Rat27 was genotyped with 10 microsatellite markers (Proligo, Paris, France). Primer sequences are found on www.ensembl.org or http://rgd.mcw.edu. PCR amplification was carried out as previously described 37 with [g- 33 P] ATP end-labeled forward primers. The PCR products were size fractioned on 6% polyacrylamide gels and visualized by autoradiography. Two independent observers evaluated all genotypes manually.
Linkage analysis
Linkage analysis was carried out in R/qtl 1.08, 38 using the Haley-Knott regression model, with sex and breeding couple as covariates. The confidence interval was defined using the markers outside a 1.5 reduction in LOD score approximately equivalent to a 95% confidence interval. 39 In order to better define the position of the QTL within the mapped region, the probability for the location of a QTL was calculated using a bootstrap approach. Simulated pedigrees were sampled with replacement from the observed AIL individuals to create a new dataset with the same number of samples (794), which was mapped using a single-QTL model in R/qtl. The maximum LOD and the location of that maximum were recorded and the re-sampling was repeated 1000 times to obtain an estimate of the probability of a QTL being present within the confidence interval of the QTL.
Expression analysis
The thirteenth generation of the AIL was produced from 25 breeding couples, and offspring was genotyped as described above, with microsatellite markers D10G97 and D10Rat98, flanking the identified QTL. In all, 51 animals were homozygous for DA (19 rats) or PVG.av1 (32 rats) at both markers. The background was not genotyped. Animals (12 weeks old) were immunized with MOG, as describe above, and on day 7 post immunization, animals were killed using CO 2 and inguinal lymph nodes were dissected out and snapfrozen in microtubes and stored at À70 1C until use. For expression analysis in the parental DA and PVG.av1 strains five animals of each strain were immunized, as described above, and the spinal cord and inguinal lymph nodes were dissected out when the DA animals showed EAE symptoms (X1) day 10-14, post immunization. A paired PVG.av1 animal was selected for each DA rat, and was dissected the same day as the DA rat, as PVG.av1 rats do not show EAE symptoms at this dose. Tissues were disrupted using Lysing Matrix D tubes (MP Biomedicals, Irvine, CA, USA) on a FastPrep homogenizer (MP Biomedicals) and mRNA was extracted using RNeasy mini columns (Qiagen, Hilden, Germany), including on column DNA-digestion. Reverse transcription was carried out using random hexamer primers (Gibco, Carlsbad, CA, USA) and Superscript Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed using a BioRad iQ5 iCycler Detection System (BioRad Laboratories, Hercules, CA, USA) with a three-step PCR protocol (95 1C for 10 min. followed by 40 Table 3 .
Re-sequencing
Re-sequencing templates were amplified from genomic DNA using a standard three-step PCR protocol with primers purchased from Proligo. Amplicons were extracted using PCR CleanUp (Qiagen) and used in a sequencing reaction including BigDye terminator v3.1 (Applied Biosystems, Carlsbad, CA, USA). Fragments were separated and recorded on an ABI 3100 (Applied Biosystems) and sequences were analyzed with Vector NTI software (InforMax, Carlsbad, CA, USA).
Association studies Case-control material for MS. The first Swedish MS casecontrol study (Sweden 1) consisted of 1023 subjects living in Sweden, originating from Sweden or other Nordic countries. The patients fulfilled the McDonald criteria for definite MS 40 and were recruited by neurologists at the Karolinska University Hospital. The control groups consisted of 1215 blood donors. These subjects lived in the Stockholm area and originated from Sweden or other Nordic countries. Details of the collection, as well as additional data regarding the cohort, have previously been reported. 41 To follow up our original association to MS, associated single-nucleotide polymorphisms (SNPs) were investigated in an additional 2546 patients and 3943 controls from Sweden, Norway, Denmark and Finland. Sweden 2 included 952 cases and 665 controls, Norway included 548 cases and 554 controls, Denmark included 512 cases and 553 controls, and Finland 806 cases and 1059 controls. All patients from the Nordic countries were diagnosed with MS according to the McDonald criteria 40 except in Finland, where the Poser's criteria were applied. 42 Controls from Sweden 1 and Norway are healthy blood donors and controls from Denmark are healthy blood donors and hospital staff. Controls from Finland are population based, whereas controls from Sweden 2 are matched to the MS patients with regards to age, sex and area of residence. Oral and/or written informed consent was given from all individuals involved in the study.
Case-control material for RA. A total of 2360 RA patients (wherein 1373 patients were positive for anti-citrullinated peptide antibodies (ACPA)) fulfilling the 1987 revised criteria of the American College of Rheumatology 43 and 958 population-based controls from the previously described EIRA cohort 44, 45 were included in the study. Detection of antibodies directed towards citrullinated peptides was performed using the Immunoscan-RA Mark2 ELISA test (Euro-Diagnostica, Malmö , Sweden). A level 425 U ml À1 was regarded as being positive according to instructions in the kit and as confirmed by validation at the Clinical Immunology laboratory at Uppsala University Hospital, Uppsala, Sweden.
Genotyping of human material
Genotyping in all case-control cohorts, except Finland, was performed using Taqman SNP Genotyping Assays from Applied Biosystems. PCR amplifications were performed on GeneAmp PCR System 9700 (Applied Biosystems) thermal cyclers, end-point readings on a 7900HT Real-Time PCR System (Applied Biosystems) and allele calling was carried out in SDS v1.2 software (Applied Biosystems). About 2-5 ng DNA was used in each PCR reaction. Genotyping in the Finnish cohort was performed using the Sequenom MassARRAy iPLEX Gold platform (Sequenom, San Diego, CA, USA), with 15 ng of genomic DNA/24-SNP multiplex. Genotypes were automatically called in Sequenom Typer 4.0 (Sequenom) and manually verified.
HLA typing. Human leukocyte antigen typing was conducted with sequence-specific primers using Olerup SSP HLA-A low-resolution kit and Olerup SSP DR lowresolution kit (Olerup SSP, Saltsjö baden, Sweden). For the Finnish cohort, the rs3135388 SNP was genotyped using the Sequenom iPlex platform, for the determination of the HLA-DR1*15 status.
Association
Associations including different models of allelic effects were calculated using logistic regression in the SNPassoc package 46 in R. 47 Allele frequencies and frequencies of haplotypes (including all SNPs in each gene) were estimated in Haploview 4.1 48 and haplotype frequencies were confirmed in UNPHASED 3.1. 49 No haplotypes spanning over several genes was investigated, as the markers were selected with a focus on the genes, not to represent the genetic polymorphisms in the whole region. Meta analyses were carried out using the Mantel-Haenszel method with fixed effects in the R package rmeta (http://cran.r-project.org).
CCL2 ELISA in cerebrospinal fluid (CSF)
Cell free CSF from 38 MS patients with relapsingremitting disease included in the Sweden 1 cohort and 41 patients diagnosed for other neurological diseases at the Neurological clinic at Karolinska University Hospital, Solna was used for the analysis of protein levels of chemokines. The control group consisted of 41 subjects with other neurological diseases (mean age 43.3 years, range 21-83 years; 20 females and 21 males; all without IgG oligoclonal bands in CSF) with the following diagnoses: unspecified sensory disturbance (n ¼ 9), un-
, n. pudendus damage (n ¼ 1) and syncope (n ¼ 1). All CSF samples were centrifuged and cells were separated immediately after sampling and the cell-free CSF was stored at À70 1C until use. Protein levels of CCL2, CCL7, CCL11, CCL8, CCL13 and CCL1 in CSF were measured using Duoset ELISA kits (R&D Systems, Minneapolis, MN, USA) according to manufacturer's instructions on Microlon 96 well plates (Greiner Bio-One GmbH, Frickenhausen, Germany). Only CCL2 was found in detectable levels. Values were analyzed using Mann-Whitney U test in GraphPad Prism version 5 (GraphPad, San Diego, CA, USA).
Results
High-resolution linkage analysis in rats A region on rat chromosome 10 has previously been linked to the susceptibility and severity of EAE, in crosses using the susceptible DA and the resistant PVG.av1 or ACI rat strains. 18, 19 In order to further define the region regulating EAE severity, the tenth generation of a rat AIL, 50 originating from the MHC-identical DA and PVG.av1 strains, was used for linkage analysis. A total of 10 microsatellite markers (D10Arb27-D10Rat27) in the previously defined Eae18b were genotyped in 794 AIL rats. Linkage analysis redefined the QTL to a 0.88 Mb region, linked primarily to severity of EAE, ( Figure 1 and Table 1) , with the peak marker D10Kini1 located at 70.27 Mb. The affected animals with DA genotype at D10Kini1 show longer disease duration compared with animals with heterozygous or PVG genotype (DA/DA: 17.5 days, DA/PVG: 12.0 and PVG/PVG: 8.0, P ¼ 0.0012). Additional phenotypes representing severity of EAE (cumulative and maximum EAE score) are also linked to the same peak marker (D10Kini1), and have similar confidence intervals, whereas weight loss during disease is linked to a broader, overlapping region (Table 1) . Phenotypes representing susceptibility to EAE (incidence and day of onset of EAE) as well as anti-MOG IgG subtype titers (total IgG, IgG1 and IgG2b) in sera were also investigated, but neither susceptibility phenotypes nor anti-MOG IgG titers showed any significant linkage to the region.
Further, we applied a bootstrap approach to support the linkage and to better position the most likely location of the QTL. The frequencies of the maximum LOD score within the region (Figure 1 ), obtained from 1000 resamples, indicated that the most likely location for the main effect QTL is located at the marker D10Kini1, a marker that maps between Ccl7 and Ccl11. This refined QTL described here is located within the previously defined QTL, 19 but the confidence interval is reduced from 3 to 0.88 Mb. In total, 10 genes (known and predicted) are located within the confidence interval for duration of EAE (Table 2 ), including a cluster of genes coding for chemokines Ccl2, 7, 11, 12 and 1. Ccl2 has been studied in relation to induction and relapses of EAE, 27,51,52 but all chemokines in the cluster are involved in chemotaxis and immunostimulation. We therefore investigated further all chemokine genes in the cluster for genetic regulation of neuroinflammation.
Genotype at Eae18b regulates expression of Ccl2, Ccl1 and Ccl11 A pattern of expression in both lymph nodes and spinal cord at the onset of disease that correlates with disease susceptibility indicated dysregulation of chemokine pathways during disease (Supplementary Figure 1) . The EAE resistance conferred by PVG genotype may be explained in part by the upregulation of Ccl11 and Ccl12 in the lymph node and downregulation of Ccl2 and Ccl1 in the spinal cord. To investigate if this chemokine dysregulation is genetically regulated and contributes to disease, we looked at genomic sequence and expression levels between susceptible and resistant strains. Exons of the chemokine genes were re-sequenced, but no genetic differences between the DA and PVG.av1 strains were detected (data not shown). However, when re-sequencing up to 2000 bp upstream of the transcription start sites, multiple polymorphisms were detected, indicating regulation of transcription as a likely disease modifier. In addition, the genetic influence from Eae18b on expression of chemokine genes was investigated in the thirteenth generation of the rat AIL. In total, 51 animals from 25 breeding couples were stratified according to the genotype at Eae18b (markers D10Got97 and D10Rat98) into two groups, DA or PVG homozygous. The intercrossed animals represent a highly genetically diverse background and the stratified groups will thereby only be genetically identical within, and in close proximity of the Eae18b locus. Expression of Ccl2, Ccl1 and Ccl11 mRNA in lymph nodes seven days after immunization was regulated by the genotype in the region (Figure 2 ). Susceptible DA alleles predispose for higher expression of Ccl2 and Ccl1, whereas resistant PVG alleles predispose for higher expression of Ccl11 (Figure 2 ). The lack of exonic polymorphisms between the tested rat strains in combination with the expression profiles in the stratified AIL animals and parental strains indicates genetically determined cis-regulated expression differences as the main mechanism, whereby Eae18b regulates EAE susceptibility. It furthermore puts focus on Ccl2, Ccl1 and Ccl11 and their human homologues for the regulation of neuroinflammation.
Association to CCL2, CCL13 and CCL1 in MS. Having established genetic linkage with the chemokine gene cluster with severity of experimental neuroinflammation and expression of Ccl2, Ccl1 and Ccl11, we set out to investigate the effects of genetic variances in the homologous human chemokine locus including CCL2, CCL7, CCL11, CCL8, CCL13 and CCL1 on chromosome 17 (29.6-29.7 Mb) and their impact on MS susceptibility. An initial scan in 1023 Swedish MS patients and 1215 controls (Sweden 1) using 18 SNPs revealed association to rs159313 in CCL13, using a dominant model (P ¼ 0.019) (OR:1.24 [1.04:1.48]), and suggestive associa- CC chemokines in EAE, MS and RA J Öckinger et al tion to SNPs in CCL2, CCL8 and CCL1 (Figure 3 , Supplementary Table 1a) . We then proceeded to analyze the haplotypes within the investigated genes and identified association to haplotypes within CCL2 and CCL13 ( Figure 4 and Figure 4 Genetic variants of chemokine genes are associated with multiple sclerosis (MS). Meta analysis of selected haplotypes in CCL2 (rs2857656, rs2857657, rs4586) and CCL13 (rs159313, rs2072070), and rs3136682 in CCL1, including MS cohorts from four Nordic countries. The size of the gray squares are inversely correlated to the standard error of the mean (s.e.) in each population, lines represent the odds ratio (OR) and confidence interval. Black diamonds indicate the OR and confidence interval for the combined analysis. n.a.: not analyzed. (Figure 4 , Table 3 ) (uncorrected P-values). The presented meta-analyses passed the test for heterogeneity, 53 and were analyzed using the Mantel-Haenszel method with fixed effects. One additional haplotype including a rare variant of the CCL13 gene (CC; rs159313, rs2072070) showed significant heterogeneity in allele frequency between the study groups, and was therefore excluded from the metaanalysis. However, significant association was seen in Sweden 1 and Denmark, indicating a possible importance of this rare haplotype (Table 3b) . Table 2a ), also apparent when using a multiplicative model 55, 56 for HLA-DRB1*15 and chemokine gene effects (data not shown). In contrast, no SNPs were associated to MS in the HLA-DRB1*15 negative subgroup (408 cases, 885 controls). However, no significant interaction between carrying a HLA-DRB1*15 allele and chemokine genotype was identified in a regression model, probably due to lack of sufficient power. Analyses using stratification for the protective HLA-A*02 allele or sex, respectively, were carried out but as no significant effects on the association was detected (data not shown) these variables were excluded from further analysis. Moreover, when Multiple Sclerosis Severity Score, 57 known for 906 of the Swedish patients, was used as outcome variable in a linear regression model, no association was shown between severity of MS and genotype in the chemokine genes. As HLA-DRB1*15 was identified as a possible modifier of the association in Sweden 1, the association was also evaluated in the DRB1*15-positive subgroups of Sweden 2 and cohorts from Norway, Denmark and Finland (Supplementary  Tables 2b-e) and included in a subsequent meta-analysis ( Figure 5 , Table 4 ). This analysis identified a new variant of the CCL2 haplotype (GCT; rs2857656, rs2857657, rs4586) conferring susceptibility and confirmed the association to the CCL13 haplotype (TC; rs159313, rs2072070), (Figure 5 ). Association to the CC haplotype in CCL13 or rs3136682 in CCL1 could not be tested in the DRB1*15-positive subgroups, because of low minorallele frequency.
CCL2 protein levels are upregulated in MS, and are determined by the CCL2 genotype To evaluate if the detected SNPs or haplotypes influence the protein levels of the chemokines, all chemokines included in the association studies were analyzed using ELISA. Only CCL2 was found in detectable amounts using the selected method. mRNA levels of the chemokine genes were also investigated using real-time quantitative PCR, but were undetectable in most samples (data not shown). CSF samples from 38 patients diagnosed with MS were compared with 41 control samples from individuals diagnosed with other (noninflammatory) neurological diseases. CCL2 levels in the CSF were higher in MS patients (0.35 ng ml
À1
), compared with other neurological diseases controls (0.24 ng ml À1 ), P-value ¼ 0.0048 (Figure 6a) . Furthermore, MS patients carrying the C allele of rs4586 in the CCL2 gene had higher protein levels (0.45 ng ml CC chemokines in EAE, MS and RA J Öckinger et al (Figure 6b ). The SNP rs4586 is included in the CCL2 haplotypes, and showed suggestive association in the initial scan (Sweden 1), wherein the T allele is associated with MS.
Association between chemokine gene polymorphisms and RA A number of chemokines, including CCL2, have been suggested to regulate the inflammatory processes in the joints of RA patients. 58 Production of CCL2 is upregulated in synovial fluid and sera in RA patients, 59 and in addition, a polymorphism in the proximity of CCL2 showed suggestive association to RA in a small Spanish study.
60
CCL13, produced by the chondrocytes in cartilage, is upregulated in the RA joint and enhances the proliferation of synovial cells. 61, 62 In addition, the chemokine cluster region has showed suggestive significance in a whole genome-association study of ACPA positive RA patients. 63 Therefore, we choose to include patients and controls from the Swedish EIRA cohort and genotyped 2360 RA patients (1373 ACPA positive) and 958 controls for a number of SNPs based on the association to MS. Single SNPs in CCL2 (rs4586, P ¼ 0.015, OR ¼ 1.34), CCL8 (rs3138038, P ¼ 0.0059, OR ¼ 2.37) and CCL13 (rs159313, P ¼ 0.049, OR ¼ 1.12) are associated with the risk of RA in ACPA positive set (Figure 3, Supplementary Table 1f) . When analyzing the whole group of patients, including ACPA negative patients, only the SNPs in CCL2 and CCL8 were significant. The haplotypes identified in MS were not found to be associated to RA.
Discussion
Despite many genes reported to be associated with MS, replications are generally lacking for majority, owing to the small effect of MS genes, heterogeneity, gene-gene and gene-environment interactions. Additional strategies are needed to prioritize and support some of these numerous gene associations. In this study we have used a comparative genetic approach, combining evidence from a rat model of MS and association in several casecontrol cohorts for MS, in order to confirm and dissect the contribution of a chemokine gene cluster. The highresolution linkage analysis in the tenth generation of an AIL confirmed the previously established linkage to this region, and further reduced the confidence interval to a 0.88 Mb region. The accumulation of recombinations in the AIL enabled a more precise location, compared with previous studies. We also used a bootstrap approach for a better positioning of the main genetic effect in the region. Both the bootstrap approach and the classic linkage analysis identified the same genetic location (marker D10Kini1) as the most probable for the QTL. Only 10 genes are located in the identified confidence interval in rat, including five chemokine genes (Ccl2, 7, CC chemokines in EAE, MS and RA J Öckinger et al 11, 12 and 1). Ccl2 and other chemokines in this region have been implicated as regulators of neuroinflammation 52 and regulators of infiltration of immune cells into the central nervous system during EAE. 27 The herein defined confidence intervals do, however, not include the second cluster of chemokines (including Ccl5, 9, 6, 3 and 4) located further upstream (71.61-71.76 Mb) on rat chromosome 10, also suggested as modulators of immunoreactions in EAE. 64 Using a genetically heterogeneous population of animals from the thirteenth generation of an AIL, and stratifying for the genotype in this region, some important findings were obtained. In the lymph nodes during the induction of encephalitogenic immune response, Ccl2 and Ccl1 are upregulated in animals with susceptible genotype (DA), whereas Ccl11 is upregulated in animals with the resistant genotype (PVG) in the region. As the chemokines are known to attract and activate immune cells with different specificity, it's likely that the composition and activation state of the immune cells attracted to the lymph nodes or the spinal cord by different chemokines is influenced by this differential expression. It has also been suggested that hetero-or homodimerization of chemokines can alter the signaling capability, 65 and the ratio of specific heterodimers could be affected by the differential expression seen here. However, additional studies will be required to describe the relationship between individual polymorphisms and regulation of transcription or expression. We are at present developing a congenic strain including the Eae18b locus, which will be the optimal tool for evaluating the genetic effect and molecular mechanisms of this locus in EAE.
Genetic polymorphisms in the homologous region on human chromosome 17 have been studied for involvement in MS susceptibility, [29] [30] [31] [32] as well as other autoimmune or chronic inflammatory diseases including RA, 60 myocardial infarction 66, 67 and allergy. 68 A second cluster including chemokine genes (CCL5, CCL16, CCL14, CCL15, CCL23, CCL18, CCL3 and CCL4) located further upstream has also been studied in relation to MS, but in this study we have focused on the centromeric cluster, as this was identified in the rat linkage study. Through meta-analysis of several MS cohorts from Nordic countries we could collect a large number of MS patients and controls from a relatively homogenous population and thereby identify association to haplotypes in CCL2 and CCL13, and a single marker in CCL1. The herein defined haplotypes in CCL2 and CCL13 both include one SNP (rs2857657 and rs159313, respectively), which were included in the previously defined haplotypes. 30 As the LD is high within these genes, we can hereby confirm the association of haplotypes in CCL2 and CCL13 to MS, originally suggested in a smaller study. 30 In addition, we identified association to rs3136682 in CCL1, wherein CT heterozygous state confers protection. It is interesting to note that no individuals homozygous for the T allele were found among the 3841 cases and 4046 controls included in the study, suggesting that this genotype could be fatal or that the SNP is relatively new. Associated haplotypes in both CCL2 and CCL13 were also found in the meta-analysis of the HLA-DRB1*15 positive subgroups but not in the HLA-DRB1*15 negative subgroups. In the original Swedish material, an association to rs1860184 in CCL11 was also identified in the HLA-DRB1*15 positive subgroup. It is interesting to note that the original GCC haplotype in CCL2 was not associated to MS in the HLA-DRB1*15 positive subgroup, but instead the GCT variant of the haplotype was identified. The GCT haplotype is associated to an increased risk in the HLA-DRB1*15 positive subgroup, in contrast to the GCC haplotype that is protective in the whole group. Taken together, these discrepancies between the whole cohorts and HLA-DRB1*15 positive and negative subgroups, respectively, indicate a modifying effect from the HLA locus, although no significant interaction was detected.
Single-nucleotide polymorphisms in CCL2, CCL8 and CCL13 were also shown to be associated with ACPA positive RA. Even though the haplotypes identified in MS are not associated to RA, these findings point out the importance of chemokine signaling in disease development and should encourage the investigation of these genes in other inflammatory diseases. However, not all inflammatory diseases share the same risk alleles, for example PTPN22 is associated to RA, SLE, T1D and autoimmune thyroiditis, 69, 70 but not MS or Crohn's disease. 71, 72 Most likely this reflects differences in the development of different inflammatory diseases. The discrepancies in association to the chemokine genes could thus indicate that distinct sets of chemokines orchestrate the infiltration of the target organs in MS and RA. Moreover, even when the same gene is indicated in several inflammatory diseases, individual polymorphisms may have different or even opposite effect on disease susceptibility, as seen for the ILR2A gene in MS and T1D. 73 An analogy is seen here for CCL2 and CCL13, wherein single SNPs are associated to RA but haplotypes are associated to MS.
The associations observed in the individual cohorts as well as in the meta-analyses provide solid evidence for the association to MS, even though the effects contributed from the genetic polymorphisms in the chemokine gene cluster are small. It could be speculated that the genetic polymorphism in the human chemokine cluster affects the severity of disease rather than susceptibility, as in rats. Here, the association to Multiple Sclerosis Severity Score was tested, but larger materials with even better defined variables for disease severity would be advantageous for these studies.
The association of SNPs in the chemokine gene cluster to both MS and RA prompted us to investigate the biological effects of these polymorphisms. The primary organ in MS is the central nervous system and investigation of biological processes within this organ would reveal clues to the pathogenesis of MS. However, brain biopsies are rare and post mortem samples typically involve late-stage disease or unusual circumstances. In contrast, CSF is routinely sampled from MS patients for diagnostic purposes, and may to some extent mirror the inflammatory events of the central nervous system. In this study we have established that CCL2 levels are higher in the CSF from patients with a relapsing remitting MS disease course, compared with controls. This is in contrast to a number of previous studies. 74, 75 This inconsistency between studies could reflect differences in CCL2 production during different stages of disease, differences between populations or different composition of control groups in the studies, as healthy controls are rarely used. In line with genetic association of CCL2 with MS, we could also establish an association between CCL2 genotype and CCL2 production; carrying one or two C alleles at rs4586 is associated with a higher CCL2 production, compared with a T homozygous genotype. It is interesting to note that the suggestive association to this SNP points out the T homozygous genotype as a risk factor for MS, thus indicating that the relation between CCL2 levels in CSF and MS is not straightforward.
CCL2, CCL13 and CCL1, showing association with MS, have previously been investigated for involvement in human and experimental neuroinflammation, as well as other inflammatory diseases. For example, CCL2 can bind to a number of receptors, including CCR2, 5, 10, DARC and D6, and is rather well described in MS, although the genetic association has been ambiguous until now. Indeed, CCL2 is found in MS lesions 26 and activates macrophages/microglia in secondary progressive MS.
76 CCL1 on the other hand, has only one identified receptor, CCR8, and its function in MS is unknown, but has been proposed as a regulator of macrophage activation in diabetes. 77 The structure of CCL13 was recently described 78 and little is known about its function in MS, although the expression in peripheral T cells is downregulated upon therapeutic IVIG treatment in MS. 79 Furthermore, CCL13 has been shown to be upregulated in the synovial fluid in RA patients, and is a regulator of proliferation of synovial cells. 62, 61 It is to be noted that CCL13 signals through receptors CCR2, 3, 5 and D6 as do other chemokines in this cluster (CCL7, 8 and 11) . No direct homolog of the CCL13 gene is found in rats, but the gene shows a high sequence similarity to rat Ccl11 (70%), whereas human CCL11 and rat Ccl11 share 77% sequence similarity (www.ensembl.org). We therefore hypothesize that CCL13 might be a human specific functional homolog of CCL11.
In conclusion, we have here demonstrated association between polymorphisms in a chemokine gene cluster and inflammatory diseases in both rats and humans, and suggest genetically determined regulation of expression and protein levels as the main regulatory mechanism.
